Survodutide vs Cagrilintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: BI 456906
Survodutide is an injectable dual agonist that hits both the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. It is being tested for obesity and for fatty liver disease (MASH), and it carries an FDA Breakthrough Therapy designation for MASH. It is still investigational and not approved for any use as of mid-2026.
Also: AM833, NN9838
Cagrilintide (also called AM833) is a long-acting synthetic analog of amylin, the gut-brain satiety hormone co-secreted with insulin by pancreatic beta cells. It is an investigational once-weekly injectable being developed by Novo Nordisk for obesity, most prominently as the amylin half of CagriSema (cagrilintide plus semaglutide). It is not yet approved as a standalone drug, but it has cleared phase 2 trials and is in late-stage development.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Survodutide | Cagrilintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The drug works on two fronts at once. The GLP-1 receptor arm dampens appetite, slows how fast the stomach empties, and improves blood sugar handling, the same lever that semaglutide pulls. The glucagon receptor arm is the twist: glucagon signaling raises energy expenditure and pushes the liver to burn fat rather than store it. The idea, still being proven out in trials, is that adding controlled glucagon activity to GLP-1 action burns more energy and clears liver fat faster than a GLP-1 drug alone, which is why survodutide is aimed squarely at fatty liver disease. | Cagrilintide is a non-selective agonist of the amylin and calcitonin receptor family. It activates amylin receptors (which are calcitonin receptors paired with RAMP accessory proteins) to signal satiety in the brain, slow gastric emptying, and blunt the post-meal glucagon rise. Mechanistic work in mice shows it reduces body weight mainly through amylin receptors AMY1R and AMY3R acting in the hindbrain, with the area postrema as a key entry point and downstream signaling through the nucleus of the solitary tract and parabrachial nucleus. Notably, weight loss in those studies persisted even after the acute appetite-suppressing effect faded, hinting at effects on energy balance beyond simple food-intake reduction. Chemically it is built on a pramlintide-like 37-amino-acid backbone with substitutions and a fatty-diacid chain attached to extend its half-life to roughly a week, enabling once-weekly dosing. |
| Common Dosing | Limited community data available See research protocols | 2.4 mg weekly Once weekly |
| Administration | Subcutaneous injection weekly | Subcutaneous injection once weekly |
| Typical Duration | Long-term use expected | Long-term / chronic use expected |
| Best Time to Take | Before bed or morning (fasted) | Any consistent time weekly |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the more advanced incretin dual agonists, and the human data are real, not hypothetical. In a Phase 2 MASH trial published in the New England Journal of Medicine in 2024 (Sanyal et al.), 293 biopsy-confirmed patients got weekly survodutide or placebo for 48 weeks, and MASH improved without worsening fibrosis in 47% of the 2.4 mg group and 62% of the 4.8 mg group, versus 14% on placebo. A separate Phase 2 obesity study showed weight loss up to roughly 18.7% at 46 weeks in completers. In April 2026, Boehringer Ingelheim and Zealand Pharma reported that the Phase 3 SYNCHRONIZE-1 obesity trial hit its mark with about 16.6% average weight loss. Large Phase 3 MASH trials (LIVERAGE and LIVERAGE-Cirrhosis) are ongoing. The catch worth knowing: nausea, vomiting, and other GI side effects are common, as with the whole incretin class, and final approval is not expected before 2027. | Cagrilintide has real human data, which sets it apart from most peptides in this category. In a 2021 Lancet phase 2 dose-finding trial (Lau et al.), once-weekly cagrilintide at 4.5 mg produced about 10.8% mean body weight loss over 26 weeks, beating both placebo (around 3%) and liraglutide 3.0 mg (around 9%), establishing that amylin agonism alone can drive clinically meaningful weight loss. Its bigger story is combination therapy: paired with semaglutide as CagriSema, it advanced into phase 3 REDEFINE trials for obesity and type 2 diabetes, with reported weight loss in the low 20% range, though final results came in somewhat below the most optimistic expectations. Side effects are dominated by the expected gastrointestinal effects (nausea, vomiting) common to gut-hormone drugs. As of 2026 cagrilintide is investigational and not FDA-approved on its own. The evidence is genuinely human and well-controlled here, which is rare, but it is still a drug under regulatory review rather than an approved therapy. |
Frequently Asked Questions: Survodutide vs Cagrilintide
What is the difference between Survodutide and Cagrilintide?
Survodutide is a weight loss peptide that survodutide is an injectable dual agonist that hits both the glp-1 and glucagon receptors, developed by boehringer ingelheim and zealand pharma. it is being tested for obesity and for fatty liver disease (mash), and it carries an fda breakthrough therapy designation for mash. it is still investigational and not approved for any use as of mid-2026. Cagrilintide is a weight loss peptide that cagrilintide (also called am833) is a long-acting synthetic analog of amylin, the gut-brain satiety hormone co-secreted with insulin by pancreatic beta cells. it is an investigational once-weekly injectable being developed by novo nordisk for obesity, most prominently as the amylin half of cagrisema (cagrilintide plus semaglutide). it is not yet approved as a standalone drug, but it has cleared phase 2 trials and is in late-stage development. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Survodutide or Cagrilintide?
Neither is universally "better" - the choice depends on your specific goals. Survodutide is typically used for weight loss purposes, while Cagrilintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Survodutide and Cagrilintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Survodutide and Cagrilintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.